Westerkam LL, et al. - Researchers conducted this retrospective cohort study to assess the efficacy of infliximab-abda vs infliximab administration associated with the treatment of hidradenitis suppurativa. Between 2016 and 2020, patients treated with infliximab or infliximab-abda at the dermatology clinic at the University of North Carolina at Chapel Hill were identified. The sample consisted of patients (n = 34) who met the clinical criteria for hidradenitis suppurativa and had received a continuous dose of infliximab or infliximab-abda for at least 10 weeks. This cohort study discovered that both infliximab administration and infliximab-abda administration were linked to similar and significant disease improvement as measured by the Hidradenitis Suppurativa Clinical Response. Further research is needed to determine whether infliximab-abda is a viable treatment option for hidradenitis suppurativa.